Spots Global Cancer Trial Database for Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
Official Title: An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled
Study ID: NCT00401401
Study Description
Brief Summary: The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Oregon Health Sciences Center, Portland, Oregon, United States
St-Luc University Hospital, Brussels, , Belgium
University Hospital Gasthuisberg, Leuven, , Belgium
Centre Georges-Francois Leclerc Hospital, Dijon, , France
Hopital Bretonneau Clinique d'Oncologie et Radiothérapie, Tours, , France
Nijmegen University Hospital, Nijmegen, , Netherlands
Lund University Hospital, Lund, , Sweden
Contact Details
Name: Vincent Gregoire, MD professor
Affiliation: St-Luc University Hospital, Brussels, Belgium
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
